Profound Medical (TSX:PRN) ROCE % : -70.98% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Profound Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Profound Medical's annualized ROCE % for the quarter that ended in Mar. 2024 was -70.98%.

Profound Medical ROCE % Historical Data

The historical data trend for Profound Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Profound Medical ROCE % Chart

Profound Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-55.26

-34.41

-33.46

-40.86

-56.68

Profound Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-47.05	-54.84	-58.14	-77.83	-70.98

Profound Medical ROCE % Calculation

Profound Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-37.467	/	( ( (87.516 - 5.685)	+	(58.911 - 8.541) )	/ 2 )
	=	-37.467	/	( (81.831	+	50.37)	/ 2 )
	=	-37.467	/	66.1005
	=	-56.68 %

Profound Medical's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-40.512	/	( ( (58.911 - 8.541)	+	(77.672 - 13.897) )	/ 2 )
	=	-40.512	/	( ( 50.37	+	63.775 )	/ 2 )
	=	-40.512	/	57.0725
	=	-70.98 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Profound Medical (TSX:PRN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Profound Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Profound Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Profound Medical (TSX:PRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Profound Medical Corp (TSX:PRN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PROF:USA

Address

2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5

Website

https://www.profoundmedical.com

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Executives

Abbey Klair Goodman

Senior Officer